The management, in its recent commentary with investors, said that the impact of the pandemic on water purifier business is above expectation. This was led by an e-commerce channel on establishing brand and customer recall.

The sales growth for these two businesses for the first quarter also reflected the same. It reported 10 per cent growth in the content solution business for the quarter.

The company also informed that it has launched two products during the quarter in the US market. This has taken the total tally of products to 175 US generics market.

Both the companies, which are in the same sector that is engineering, are expected to be beneficial to all. Tube Investment believes that its operations as well as financial efficiency could help in the resolution of issues going on in CG Power.

The company will work closely with various governments and medical communities to ensure easy availability of ‘Favulous’ to patients across the world.

The newly-launched drug, which was the need of the hour, would be available in the form of a strip of ten tablets, marketed under the brand name of Covihalt. It will be used to treat patients having a mild to moderate COVID-19 disease.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease.

Besides, to further expand in the Eastern region, the company had acquired Jaipur Cements in May 2019 to set up a grinding unit with 1.5 MTPA capacities at a cost of Rs 308 crore.

The numbers show a very positive trend in the re-opening of the economy. Despite this, the bank added that the overall situation continues to be uncertain. One of the major challenges that the bank sees is the extended working capital cycle and waning cash flows.

During the recently concluded Q1FY21, the company reported 14.5 per cent growth in electricity volumes at 14,878 MU in comparison to the same quarter last year.